CO5640114A2 - 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas - Google Patents

4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas

Info

Publication number
CO5640114A2
CO5640114A2 CO05081472A CO05081472A CO5640114A2 CO 5640114 A2 CO5640114 A2 CO 5640114A2 CO 05081472 A CO05081472 A CO 05081472A CO 05081472 A CO05081472 A CO 05081472A CO 5640114 A2 CO5640114 A2 CO 5640114A2
Authority
CO
Colombia
Prior art keywords
formula
chinolincarbonitrils
metoxifenil
dicloro
alcoxi
Prior art date
Application number
CO05081472A
Other languages
English (en)
Spanish (es)
Inventor
Diane Harris Boschelli
Margaret Maria Zaleska
Frank Charles Boschelli
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5640114(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5640114A2 publication Critical patent/CO5640114A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO05081472A 2003-02-21 2005-08-17 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas CO5640114A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
CO5640114A2 true CO5640114A2 (es) 2006-05-31

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05081472A CO5640114A2 (es) 2003-02-21 2005-08-17 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas

Country Status (19)

Country Link
US (1) US20040229880A1 (https=)
EP (1) EP1594502A1 (https=)
JP (1) JP2006522023A (https=)
KR (1) KR20050102133A (https=)
CN (1) CN1750824A (https=)
AR (1) AR043253A1 (https=)
AU (1) AU2004216235A1 (https=)
BR (1) BRPI0407441A (https=)
CA (1) CA2516418A1 (https=)
CO (1) CO5640114A2 (https=)
CR (1) CR7931A (https=)
EC (1) ECSP055972A (https=)
MX (1) MXPA05008706A (https=)
NO (1) NO20054070L (https=)
RU (1) RU2005129333A (https=)
TW (1) TW200423938A (https=)
UA (1) UA80472C2 (https=)
WO (1) WO2004075898A1 (https=)
ZA (1) ZA200506621B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
JP2008517924A (ja) * 2004-10-22 2008-05-29 ワイス 虚血傷害を処置するための4−[(2,4−ジクロロ−5−メトキシフェニル)アミノ]−6−アルコキシ−7−エチニル−3−キノリンカルボニトリル
EP1902029B2 (en) * 2005-07-01 2022-02-16 Wyeth LLC Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
ES2565627T3 (es) * 2010-07-30 2016-04-06 Oncotherapy Science, Inc. Derivados de quinolina e inhibidores de MELK que contienen los mismos
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
EP3227276B1 (en) 2014-12-02 2021-09-01 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CA2500368A1 (en) * 2002-10-04 2004-04-22 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
ZA200506621B (en) 2008-02-27
JP2006522023A (ja) 2006-09-28
ECSP055972A (es) 2006-01-16
NO20054070L (no) 2005-11-14
CA2516418A1 (en) 2004-09-10
AU2004216235A1 (en) 2004-09-10
KR20050102133A (ko) 2005-10-25
AR043253A1 (es) 2005-07-20
EP1594502A1 (en) 2005-11-16
BRPI0407441A (pt) 2006-01-31
WO2004075898A1 (en) 2004-09-10
TW200423938A (en) 2004-11-16
US20040229880A1 (en) 2004-11-18
NO20054070D0 (no) 2005-09-01
CR7931A (es) 2006-02-07
RU2005129333A (ru) 2006-01-27
CN1750824A (zh) 2006-03-22
MXPA05008706A (es) 2005-10-05
UA80472C2 (en) 2007-09-25

Similar Documents

Publication Publication Date Title
CO5640114A2 (es) 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas
PA8544901A1 (es) Derivados de oxazol
UY27918A1 (es) Derivados de benzodioxol
ECSP045003A (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos.
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
CY1118572T1 (el) Παραγωγο κυκλοαλκανιου
UY26872A1 (es) Derivados de la 4- fenil piridina
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
AR060749A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
UY28695A1 (es) Derivados de difenilazetidona
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
RU2005105564A (ru) Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
UY27338A1 (es) Nuevos derivados de ácido sulfónico
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
PA8581201A1 (es) Nuevos derivados de tiazol
PA8589801A1 (es) Aminoalcoxiindoles
TW200643139A (en) π-conjugated compound having cardo structure, process for preparing same and use of same
MXPA04001277A (es) Imidazopiridinas triciclicas.
PY0435702A (es) Mezclas fungicidas a base de derivados de carbamato e insecticidas
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina

Legal Events

Date Code Title Description
FC Application refused